多发性骨髓瘤患者血清IL-18和sVCAM-1的水平及临床意义  

Clinical Significance of Serum IL-18 and sVCAM-1 in Patients with Multiple Myeloma

作　　者：巫远忠[1] 刘瑞玉[1] 刘得智 

机构地区：[1]广东惠州中心人民医院,惠州516001

出　　处：《热带医学杂志》2010年第7期856-857,863,共3页Journal of Tropical Medicine

摘　　要：目的探讨多发性骨髓瘤患者血清白细胞介素18(IL-18)和可溶性血管细胞黏附分子-1(sVCAM-1)的水平及临床意义。方法应用ELISA法检查15例多发性骨髓瘤患者治疗前的血清IL-18和sVCAM-1的水平,并与正常对照进行比较。结果多发性骨髓瘤患者血清IL-18和sVCAM-1的水平[(1154.6±299)pg/ml和(1704.5±405.86)ng/ml]明显高于正常对照组[(256.39±59)pg/ml和(538.16±91.21)ng/ml]。结论多发性骨髓瘤患者血清IL-18、sVCAM-1含量明显增高,可能与多发性骨髓瘤的发病机制有关。Objective To investigate the levels and its clinical significance of serum interleukin-18（IL-18）and soluble vascular cell adhesion molecule-1（sVCAM-1）in patients with multiple myeloma.Methods The levels of serum IL-18 and sVCAM-1 of 15 patients with mutiple myeloma were assayed by ELISA.Serum from the normal health subjects was used as control.Results The levels of serum IL-18 and sVCAM-1 in patients with multiple myeloma [（1154.6±299）pg /ml and（1704.5±405.86）ng /ml] were significantly higher than that of the control group [（256.39±59）pg /ml and（538.16±91.21）ng /ml].Conclusion The elevated levels of serum IL-18 and sVCAM-1 may be associated with the onset mechanism of mutiple myeloma.

关 键 词：多发性骨髓瘤 白细胞介素18 可溶性血管细胞黏附分子-1 

分 类 号：R733.3[医药卫生—肿瘤]